EDGEMOND JAMES sold $5.5M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 10,000 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.17 ($538.52–$553.76, $5.49M total) across 14 trades on 2026-06-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, time-stamped record of insider selling ($5.49M) executed across 14 trades on 2026-06-15, filed on 2026-06-16, with a stated 10b5-1 plan.
Market read
Primarily a sentiment/positioning datapoint for UTHR; not a fundamental catalyst by itself.
What to watch
Traders may overreact to insider sales; the key is whether there are repeated consecutive Form 4 sales or other concurrent fundamental catalysts (not present here).
Background
SEC Form 4 reports an insider transaction by Edgemond James (CFO and Treasurer) for United Therapeutics.
Ticker impact
United Therapeutics officer sold $5.49M of shares via an open-market transaction under a pre-arranged 10b5-1 plan.
Likely limited/short-lived impact; watch for follow-on selling or unusual volume around the filing date.
Form 4 is a primary disclosure, but the sale is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.
Market effects
No sector-level read-across; this is company-specific insider transaction disclosure.
None indicated beyond UTHR-specific sentiment.
None indicated.
Counterpoint
Because the trades were executed under a pre-arranged 10b5-1 plan, the selling may reflect routine liquidity/compensation rather than bearish fundamentals.
Key entities
- issuerUnited Therapeutics Corp
Company whose shares were sold by an officer under a 10b5-1 plan.
- insiderEdgemond James
CFO and Treasurer who executed the open-market sale.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically reduces the informational content of insider sales.
